53 completed. 53 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 53 | Completed 53 |
| Phase 2 | 3 | Completed 3 |
Follow Vision Disorders: new trials by email Literature Review of Vision Disorders trials Research Report on Vision Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR) Tarcocimab, Sham injection - Diabetic Retinopathy | Phase 3 | Completed | Kodiak Sciences Inc | 255 | 2024-05-01 | 2026-05-13 |
| Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy Brolucizumab 6mg - Macular Polypoidal Choroidal Vasculopathy (PCV) | Phase 3 | Completed | Novartis Pharmaceuticals | 148 | 2023-02-06 | 2025-12-15 |
| A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) KSI-301, Aflibercept, Sham Procedure - Wet Age-related Macular Degeneration | Phase 3 | Completed | Kodiak Sciences Inc | 557 | 2021-06-23 | 2024-07-03 |
| An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study brolucizumab - Neovascular Age-related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 248 | 2020-12-16 | 2024-10-09 |
| Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration RTH258/Brolucizumab - Neovascular Age-Related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 295 | 2020-12-14 | 2024-11-07 |
| Randomized Trial in Adult Participants With Acute Migraines Zavegepant, Placebo - Migraine | Phase 3 | Completed | Pfizer | 1978 | 2020-10-27 | 2023-04-24 |
| A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) KSI-301, Aflibercept, Sham Procedure - Macular Edema, Retinal Vein Occlusion | Phase 3 | Completed | Kodiak Sciences Inc | 568 | 2020-09-25 | 2024-06-26 |
| A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection - Diabetic Retinopathy | Phase 3 | Completed | Hoffmann-La Roche | 174 | 2020-08-10 | 2026-04-02 |
| Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO treatment - Arteritis, Giant Cell, Blindness and Low Vision | Phase 3 | Completed | Centre Hospitalier Universitaire de Nice | 8 | 2020-02-04 | 2026-06-18 |
| Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration Brolucizumab 6mg, Aflibercept 2 mg - Neovascular Age-Related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 397 | 2019-11-29 | 2024-12-09 |
| Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) Brolucizumab 6 mg, Aflibercept 2 mg - Age-related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 734 | 2019-09-25 | 2024-10-09 |
| Acute Treatment Trial in Adult Subjects With Migraines Zavegepant, Zavegepant matching placebo, Intranasal Aptar Pharma Unit Dose System - Migraine | Phase 2 / Phase 3 | Completed | Pfizer | 2154 | 2019-03-25 | 2023-09-25 |
| mHealth Intervention for Improving Eye Health at Community Level Screening program including 2 consecutive tests, Screening program with mobile health - Visual Impairment | Phase 3 | Completed | Shahid Beheshti University of Medical Sciences | 3300 | 2017-04-15 | 2019-04-23 |
| A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients Ranibizumab (RFB002), Laser, Sham injection - Diabetic Macular Edema, Visual Impairment | Phase 3 | Completed | Novartis Pharmaceuticals | 384 | 2014-11-05 | 2019-02-01 |
| Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration Aflibercept - Macular Degeneration, Wet Macular Degeneration | Phase 3 | Completed | Centre Hospitalier Intercommunal Creteil | 84 | 2013-12-01 | 2026-10-27 |
| Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) Ranibizumab 0.5 mg, Sham injection - Macular Edema Secondary to Branch Retinal Vein Occlusion | Phase 3 | Completed | Novartis Pharmaceuticals | 283 | 2013-11-12 | 2017-05-08 |
| Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) Sham injection, Ranibizumab 0.5 mg - Central Retinal Vein Occlusion | Phase 3 | Completed | Novartis Pharmaceuticals | 252 | 2013-11-12 | 2017-05-30 |
| To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema Sham control, Ranibizumab - Macular Edema (ME) | Phase 3 | Completed | Novartis Pharmaceuticals | 181 | 2013-10-01 | 2016-05-23 |
| Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization. Ranibizumab, Sham control - Choroidal Neovascularization (CNV) | Phase 3 | Completed | Novartis Pharmaceuticals | 183 | 2013-09-01 | 2016-08-26 |
| A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion Ocriplasmin, Sham injection - Symptomatic Vitreomacular Adhesion | Phase 3 | Completed | Alcon Research | 251 | 2013-07-01 | 2015-11-30 |
Showing 20 of 53. Sign in to see all of them.
Amblyopia (14) · Macular Edema (12) · Eye Diseases (11) · Blindness (10) · Macular Degeneration (9) · Retinal Diseases (9) · Retinal Vein Occlusion (8) · Choroidal Neovascularization (5) · Retinal Degeneration (5) · Wet Macular Degeneration (5) · Diabetes Mellitus (4) · Diabetic Retinopathy (4) · Chronobiology Disorders (3) · Dyssomnias (3)
Neurologic Manifestations (53) · Pathological Conditions, Signs and Symptoms (53) · Sensation Disorders (53) · Signs and Symptoms (53) · Nervous System Diseases (50) · Eye Diseases (42) · Brain Diseases (19) · Central Nervous System Diseases (19) · Retinal Diseases (19) · Retinal Degeneration (17) · Cardiovascular Diseases (14) · Vascular Diseases (13) · Macular Degeneration (12) · Embolism and Thrombosis (8)
Ranibizumab (14) · salicylhydroxamic acid (8) · aflibercept (7) · Atropine (6) · brolucizumab (5) · Lasers (3) · tasimelteon (3) · Aspirin (2) · Dexamethasone (2) · Eyeglasses (2) · Acetaminophen (1) · Acetazolamide (1) · Codeine (1) · Diclofenac (1) · Ibuprofen (1)
Novartis Pharmaceuticals (15) · Jaeb Center for Health Research (12) · Kodiak Sciences Inc (3) · National Eye Institute (NEI) (3) · Vanda Pharmaceuticals (3) · Bayer (2) · Genentech, Inc. (2) · Pfizer (2) · Thomas Jefferson University (2) · Alcon Research (1) · Centre Hospitalier Intercommunal Creteil (1) · Centre Hospitalier Universitaire de Nice (1) · Erasmus Medical Center (1) · Hoffmann-La Roche (1) · NICHD Neonatal Research Network (1)
United States (29) · France (10) · Germany (10) · Czechia (8) · Hungary (7) · Italy (7) · South Korea (7) · Spain (7) · United Kingdom (7) · Australia (6) · Canada (6) · Poland (6) · Switzerland (6) · Israel (5) · Netherlands (5)
David K. Wallace, M.D. (3) · Pablo Velazquez-Martin, MD (3) · Jason Ehrlich, M.D., Ph.D. (2) · Michael X Repka, M.D. (2) · Mitchell M. Scheiman, O.D. (2) · Richard W. Hertle, M.D. (2) · Susan A. Cotter, O.D. (2) · Alan R. Spitzer, MD (1) · Barbara J. Stoll, MD (1) · Beverly S. Brozanski, MD (1) · Charles C. Barr, MD (1)
PMID 20451898, PMID 22108357, PMID 22965590, PMID 23706949, PMID 24768239, PMID 25148789, PMID 26050541, PMID 26452713, PMID 26466871, PMID 26584450, PMID 26992841, PMID 27234930, PMID 29752001, PMID 30419298, PMID 31047350, PMID 31047503, PMID 31668888, PMID 36774994, PMID 37585454, PMID 39680390, PMID 10654946, PMID 16751032, PMID 16751033, PMID 17679633, PMID 18789533, PMID 19064841, PMID 19139333, PMID 19541265, PMID 20163869, PMID 21419678, PMID 22633344, PMID 23084240, PMID 23528439, PMID 23755872, PMID 24084500, PMID 24756302, PMID 24756514, PMID 24781936, PMID 24789375, PMID 25016366, PMID 25107900, PMID 25370510, PMID 25370513, PMID 25439429, PMID 25676904, PMID 25727586, PMID 26024112, PMID 26335066, PMID 26618282, PMID 26778344
U10EY011751 (12), 2019 (2), M01RR000054 (1), M01RR000070 (1), R01MH061331 (1), U10EY017281 (1), U10EY017387 (1), U10HD021385 (1), U10HD021415 (1), U10HD027851 (1), U10HD027853 (1), U10HD027856 (1), U10HD027871 (1), U10HD027880 (1), U10HD027904 (1)